

INCOME STATEMENT
Three months ended 30th June 2007

	Q2 2007 £m	Q2 2006 £m	Growth	
			CER%	£%
Turnover:				
Pharmaceuticals	4,775	5,021	-	(5)
Consumer Healthcare	899	790	18	14
TURNOVER	5,674	5,811	3	(2)
Cost of sales	(1,212)	(1,209)	3	-
Gross profit	4,462	4,602	3	(3)
Selling, general and administration	(1,841)	(1,883)	3	2
Research and development	(789)	(853)	(4)	8
Other operating income	97	45		
Operating profit:				
Pharmaceuticals	1,749	1,748	9	-
Consumer Healthcare	180	163	15	10
OPERATING PROFIT	1,929	1,911	9	1
Finance income	77	67		
Finance expense	(121)	(93)		
Share of after tax profits of associates and joint ventures	11	12		
PROFIT BEFORE TAXATION	1,896	1,897	8	-
Taxation	(541)	(560)		
<i>Tax rate</i>	28.5%	29.5%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,355	1,337	10	1
Profit attributable to minority interests	22	22		
Profit attributable to shareholders	1,333	1,315		
	1,355	1,337		
EARNINGS PER SHARE	24.0p	23.3p	11	3
Diluted earnings per share	23.7p	23.0p		

INCOME STATEMENT
Six months ended 30th June 2007

	H1 2007 £m	H1 2006 £m	Growth	
			CER%	£%
Turnover:				
Pharmaceuticals	9,581	10,066	2	(5)
Consumer Healthcare	1,685	1,558	14	8
TURNOVER	11,266	11,624	3	(3)
Cost of sales	(2,446)	(2,343)	8	4
Gross profit	8,820	9,281		(6)
Selling, general and administration	(3,514)	(3,706)	1	(5)
Research and development	(1,515)	(1,606)	(1)	(6)
Other operating income	304	116		
Operating profit:				
Pharmaceuticals	3,777	3,782	10	-
Consumer Healthcare	318	303	11	5
OPERATING PROFIT	4,095	4,085	10	-
Finance income	135	140		
Finance expense	(217)	(185)		
Share of after tax profits of associates and joint ventures	26	27		
PROFIT BEFORE TAXATION	4,039	4,067	9	(1)
Taxation	(1,151)	(1,200)		
<i>Tax rate</i>	28.5%	29.5%		
PROFIT AFTER TAXATION FOR THE PERIOD	2,888	2,867	11	1
Profit attributable to minority interests	41	50		
Profit attributable to shareholders	2,847	2,817		
	2,888	2,867		
EARNINGS PER SHARE	51.0p	49.8p	12	2
Diluted earnings per share	50.4p	49.2p		

PHARMACEUTICAL TURNOVER
Three months ended 30th June 2007

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,260	8	2	593	10	2	452	4	2	215	8	3
Seretide/Advair	871	12	6	467	11	3	313	8	7	91	25	20
Flixotide/Flovent	151	(2)	(8)	65	3	(6)	41	(9)	(9)	45	(4)	(10)
Serevent	70	(1)	(5)	18	(5)	(14)	35	(3)	(3)	17	6	-
Flixonase/Flonase	55	(15)	(19)	25	(26)	(26)	16	(6)	(6)	14	-	(18)
CENTRAL NERVOUS SYSTEM	828	(3)	(10)	586	(2)	(9)	128	(14)	(16)	114	2	(7)
Seroxat/Paxil	140	(4)	(12)	34	(8)	(15)	32	(13)	(16)	74	1	(9)
Paxil IR	103	(8)	(16)	2	(75)	(75)	32	(13)	(16)	69	1	(9)
Paxil CR	37	8	-	32	9	-	-	-	-	5	-	-
Wellbutrin	132	(40)	(44)	128	(41)	(45)	-	-	-	4	(20)	(20)
Wellbutrin IR, SR	15	(41)	(44)	12	(46)	(50)	-	-	-	3	-	-
Wellbutrin XL	117	(40)	(44)	116	(40)	(44)	-	-	-	1	(50)	(50)
Imigran/Imitrex	167	2	(5)	136	10	1	22	(27)	(27)	9	(9)	(18)
Lamictal	271	18	11	221	28	19	36	(22)	(22)	14	15	8
Requip	84	41	31	59	54	44	22	10	10	3	67	-
ANTI-VIRALS	755	11	5	366	15	6	230	7	6	159	9	1
HIV	364	(3)	(7)	159	(5)	(13)	156	(3)	(4)	49	6	2
Combivir	117	(13)	(17)	50	(13)	(21)	51	(12)	(12)	16	(20)	(20)
Trizivir	60	(13)	(17)	32	(11)	(16)	24	(10)	(17)	4	(40)	(20)
Epivir	40	(21)	(25)	12	(22)	(33)	18	(24)	(28)	10	(10)	-
Ziagen	27	(3)	(7)	11	-	(8)	10	(10)	-	6	-	(14)
Agenerase, Lexiva	33	9	3	19	11	6	13	8	8	1	-	(50)
Epzicom/Kivexa	79	43	36	36	22	13	36	57	57	7	>100	>100
Herpes	252	11	3	162	15	7	38	6	6	52	2	(10)
Valtrex	226	14	6	161	16	8	30	7	7	35	8	(5)
Zovirax	26	(10)	(16)	1	(50)	(50)	8	-	-	17	(10)	(19)
Zeffix	44	15	10	3	33	-	6	-	-	35	16	13
Relenza	67	>100	>100	34	-	-	26	>100	>100	7	-	-
METABOLIC	420	(16)	(21)	252	(27)	(32)	79	31	30	89	(3)	(7)
Avandia products	349	(22)	(27)	226	(31)	(37)	63	20	17	60	(9)	(10)
Avandia	249	(35)	(39)	169	(42)	(46)	31	(3)	(6)	49	(17)	(18)
Avandamet	85	41	33	45	30	22	31	52	48	9	67	50
Avandaryl	15	>100	>100	12	>100	>100	1	-	-	2	-	-
Bonviva/Boniva	36	>100	89	26	75	63	10	>100	>100	-	-	-
VACCINES	398	6	3	105	27	17	178	3	2	115	(3)	(6)
Hepatitis	128	10	6	47	21	12	59	5	2	22	-	5
Influenza	4	(43)	(43)	-	-	-	-	-	-	4	(57)	(43)
Infanrix/Pediarix	135	9	5	51	44	31	66	(13)	(13)	18	36	29
Boostrix	14	-	-	7	(11)	(22)	5	25	25	2	-	100
Rotarix	15	>100	>100	-	-	-	6	>100	>100	9	>100	>100
CARDIOVASCULAR AND UROGENITAL	439	22	15	292	39	28	103	3	1	44	(13)	(17)
Coreg	202	37	26	199	37	26	-	-	-	3	-	50
Coreg CR	10	-	-	9	-	-	-	-	-	1	-	-
Coreg IR	192	30	20	190	30	20	-	-	-	2	-	-
Levitra	11	44	22	11	50	38	-	-	-	-	-	-
Avodart	67	39	31	40	47	33	21	24	24	6	50	50
Arixtra	26	>100	100	14	>100	>100	10	83	67v	2	-	100
Fraxiparine	45	(18)	(20)	-	-	-	40	(15)	(15)	5	(33)	(44)
Vesicare	12	86	71	12	86	71	-	-	-	-	-	-
ANTI-BACTERIALS	310	(2)	(5)	49	17	7	131	(11)	(12)	130	2	(1)
Augmentin	120	(8)	(10)	17	(6)	(6)	52	(20)	(19)	51	6	(2)
ONCOLOGY AND EMESIS	126	(55)	(56)	75	(65)	(67)	34	(17)	(19)	17	(14)	(19)
Zofran	55	(76)	(76)	25	(86)	(86)	17	(42)	(45)	13	(13)	(13)
Hycamtin	28	4	-	16	-	(6)	10	22	11	2	(50)	-
Tykerb	12	-	-	10	-	-	2	-	-	-	-	-
OTHER	239	3	-	9	(59)	(59)	67	6	5	163	11	7
Zantac	40	(31)	(34)	5	(74)	(74)	11	(14)	(21)	24	(11)	(14)
	4,775	-	(5)	2,327	(2)	(9)	1,402	1	-	1,046	3	(2)

Pharmaceutical turnover includes co-promotion income.

PHARMACEUTICAL TURNOVER
Six months ended 30th June 2007

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	2,484	4	(2)	1,175	3	(6)	884	4	2	425	9	-
<i>Serotide/Advair</i>	1,706	11	4	926	12	1	607	8	7	173	19	11
<i>Flixotide/Flovent</i>	306	(4)	(11)	136	(3)	(12)	83	(9)	(10)	87	1	(8)
<i>Serevent</i>	135	(3)	(9)	37	(7)	(16)	67	(6)	(7)	31	6	(3)
<i>Flixonase/Flonase</i>	118	(37)	(41)	50	(60)	(61)	29	(3)	(3)	39	10	(5)
CENTRAL NERVOUS SYSTEM	1,624	(3)	(10)	1,151	-	(9)	256	(18)	(19)	217	4	(6)
<i>Seroxat/Paxil</i>	274	(7)	(14)	71	(16)	(24)	66	(15)	(16)	137	4	(7)
<i>Paxil IR</i>	196	(8)	(16)	2	(86)	(86)	66	(15)	(16)	128	4	(8)
<i>Paxil CR</i>	78	(2)	(11)	69	(4)	(13)	-	-	-	9	11	-
<i>Wellbutrin</i>	264	(37)	(42)	256	(37)	(42)	1	-	-	7	(13)	(13)
<i>Wellbutrin IR, SR</i>	38	(22)	(25)	32	(24)	(29)	1	-	-	5	-	-
<i>Wellbutrin XL</i>	226	(38)	(44)	224	(39)	(44)	-	-	-	2	(33)	(33)
<i>Imigran/Imitrex</i>	333	2	(7)	272	11	1	43	(34)	(36)	18	(5)	(14)
<i>Lamictal</i>	521	18	8	421	29	17	71	(23)	(24)	29	14	4
<i>Requip</i>	164	45	34	115	62	47	43	10	10	6	60	20
ANTI-VIRALS	1,523	15	7	751	21	10	456	9	7	316	12	2
HIV	723	(3)	(9)	323	(2)	(11)	308	(4)	(6)	92	(1)	(10)
<i>Combivir</i>	232	(13)	(18)	100	(11)	(20)	100	(14)	(15)	32	(17)	(24)
<i>Trizivir</i>	122	(10)	(15)	64	(7)	(15)	51	(13)	(16)	7	(13)	(13)
<i>Epiriv</i>	81	(24)	(28)	26	(24)	(32)	36	(27)	(29)	19	(17)	(21)
<i>Ziagen</i>	53	(7)	(13)	22	(4)	(12)	19	(10)	(10)	12	(7)	(20)
<i>Agenerase, Lexiva</i>	68	12	5	39	16	5	26	8	8	3	-	(25)
<i>Epzicom/Kivexa</i>	154	50	41	71	28	16	69	67	64	14	>100	>100
Herpes	502	14	4	328	22	11	74	4	3	100	(1)	(12)
<i>Valtrex</i>	450	17	8	325	22	11	58	9	7	67	4	(7)
<i>Zovirax</i>	52	(11)	(17)	3	(25)	(25)	16	(11)	(11)	33	(10)	(20)
<i>Zeffix</i>	84	15	8	6	17	-	12	9	9	66	16	8
<i>Relenza</i>	159	>100	>100	78	>100	>100	58	>100	>100	23	>100	>100
METABOLIC	896	1	(7)	569	(6)	(15)	150	28	26	177	8	-
<i>Avandia products</i>	763	(4)	(11)	520	(10)	(18)	120	16	14	123	11	3
<i>Avandia</i>	564	(18)	(25)	401	(24)	(31)	62	(3)	(5)	101	1	(6)
<i>Avandamet</i>	168	96	83	92	>100	>100	57	45	43	19	91	73
<i>Avandaryl</i>	31	100	82	27	88	69	1	-	-	3	>100	>100
<i>Bonviva/Boniva</i>	68	>100	100	49	80	63	19	>100	>100	-	-	-
VACCINES	766	6	2	187	19	8	350	4	3	229	-	(5)
<i>Hepatitis</i>	241	7	2	79	11	-	115	4	2	47	9	4
<i>Influenza</i>	5	(38)	(38)	-	-	-	-	-	-	5	(38)	(38)
<i>Infanrix/Pediarix</i>	269	12	6	94	30	18	139	(2)	(3)	36	31	24
<i>Boostrix</i>	27	17	13	14	14	-	9	29	29	4	-	33
<i>Rotarix</i>	29	>100	>100	-	-	-	10	>100	>100	19	82	73
CARDIOVASCULAR AND UROGENITAL	878	17	9	595	25	14	203	5	3	80	(3)	(10)
<i>Coreg</i>	419	20	9	414	20	8	-	-	-	5	33	67
<i>Coreg CR</i>	24	-	-	23	-	-	-	-	-	1	-	-
<i>Coreg IR</i>	395	13	3	391	13	2	-	-	-	4	33	33
<i>Levitra</i>	25	40	25	24	50	33	-	-	-	1	-	-
<i>Avodart</i>	130	43	33	81	55	40	39	18	18	10	57	43
<i>Arixtra</i>	46	>100	92	25	>100	92	19	100	90	2	-	100
<i>Fraxiparine</i>	92	(12)	(14)	-	-	-	82	(9)	(10)	10	(31)	(38)
<i>Vesicare</i>	23	79	64	23	79	64	-	-	-	-	-	-
ANTI-BACTERIALS	658	(2)	(7)	102	4	(6)	306	(6)	(7)	250	-	(6)
<i>Augmentin</i>	267	(9)	(12)	41	(10)	(16)	125	(14)	(15)	101	-	(6)
ONCOLOGY AND EMESIS	273	(50)	(53)	175	(59)	(61)	66	(18)	(20)	32	(21)	(26)
<i>Zofran</i>	142	(68)	(69)	81	(77)	(78)	37	(38)	(39)	24	(26)	(29)
<i>Hycamtin</i>	58	9	2	35	5	(5)	19	25	19	4	(25)	-
<i>Tykerb</i>	16	-	-	13	-	-	3	-	-	-	-	-
OTHER	479	4	(2)	41	(4)	(13)	123	2	1	315	6	(1)
<i>Zantac</i>	88	(25)	(30)	21	(43)	(48)	21	(21)	(25)	46	(14)	(21)
	9,581	2	(5)	4,746	1	(8)	2,794	1	-	2,041	5	(3)

Pharmaceutical turnover includes co-promotion income.

CONSUMER HEALTHCARE TURNOVER
Three months ended 30th June 2007

	Q2 2007 £m	Growth	
		CER%	£%
Over-the-counter medicines	446	29	22
Analgesics	103	7	4
Dermatological	44	2	(2)
Gastrointestinal	66	11	5
Respiratory tract	44	31	26
Smoking control	75	(5)	(11)
Natural wellness support	29	(3)	(3)
Weight management	76	-	-
Oral care	266	9	5
Nutritional healthcare	187	9	9
Total	899	18	14

CONSUMER HEALTHCARE TURNOVER
Six months ended 30th June 2007

	H1 2007 £m	Growth	
		CER%	£%
Over-the-counter medicines	821	18	11
Analgesics	200	9	3
Dermatological	84	5	(1)
Gastrointestinal	132	11	3
Respiratory tract	100	39	32
Smoking control	153	(7)	(14)
Natural wellness support	59	(3)	(8)
Weight management	76	-	-
Oral care	514	9	4
Nutritional healthcare	350	10	8
Total	1,685	14	8